PluroGen Therapeutics, Inc.
503 Broadleaf Way
Charlottesville, VA 22911
Tel: 443 994 0101
Fax: 410 990 9817
www.plurogen.com
503 Broadleaf Way
Charlottesville, VA 22911
Tel: 443 994 0101
Fax: 410 990 9817
www.plurogen.com
| News Release |
FOR IMMEDIATE RELEASE Contact: Neal G. Koller
President & CEO
11 May 2009 Board of Directors
443 994 0101
PLUROGEN THERAPEUTICS INC. & WELCARE INDUSTRIES, S.p.a.
SIGN LETTER OF INTENT TO
COMMERCIALIZE PLUROGEL™ - BASED PRODUCTS IN THE US
(Charlottesville, VA, May 12, 2009) – PluroGen Therapeutics, Inc. today announced a Letter of Intent with
Welcare Industries S.p.a. (Orvieto, Italy) to submit for US medical device approval and commence sales in
the US market of Welcare’s PluroGel™-based wound & skin cleansing product line.
Commenting on the Letter of Intent, Neal G. Koller, President & CEO of PluroGen, said, “We are pleased
Welcare has seen success in Europe with their PluroGel™-based skin & wound cleansing medical device
line and is now ready to bring these products to the US market. This is a terrific commercial opportunity
for PluroGen furthering our marketing strategy to offer multiple products with a variety of purposes based
on our core gel technology.”
Fulvia Lazzarotto, Managing Director for Welcare, commented that “We are looking forward to duplicating
the European success of our PluroGel™ based products in the US market. We are very happy PluroGen
will be working with us for this project, they are the ideal partner”.
About PluroGen Therapeutics, Inc.
PluroGen is a skin care and wound healing company commercializing our core patent-protected gel
technology platform that provides superior and differentiated physical, bio-impact and multi-function
benefits. Our multiple technology platforms are configurable to deliver drug and non-drug compounds as
protected and advanced therapeutic and topical products for simple and complex skin care, burn and
wound healing. PluroGen’s product pipeline targets improved, protected therapies for the 6 areas of
treatment in tissue management and healing (cleansing, infection, pain, inflammation, tissue salvage,
tissue regeneration).
PluroGen’s first gels, PluroGel™ and ActiviGel™, are being used initially in skin and wound cleansing
products, for personal skin care products and for two branded topical antimicrobial products, PluroGel™
Barrier Gels and PluroGel™ Barrier Dressings. PluroGel™ / ActiviGel™ technology is currently in routine use
at the University of Virginia Medical Center, having shown superior results on more than 2,000 patients in
two different patient populations, severe burns and chronic wounds. The PluroGen management and
operational teams, Boards and Principal Investigators are recognized global clinical and commercial
leaders in PluroGen’s target markets of burn and wound care and in the life sciences industry.
For more information about PluroGen Therapeutics, Inc., visit the Company’s web site at www.plurogen.com.
About the Welcare Industries, S.p.a.
Welcare Industries, S.p.a. is a privately held European medical device company with manufacturing,
distribution and headquarters in Orvieto, Italy. Welcare was founded in 1997 and focuses on wound and
total patient cleansing products, clinical and patient protection products and specialty procedure products.
Welcare is currently selling its products in major European countries.
For more information about Welcare Industries, S.p.a., visit the Company’s web site at www.welcaremedical.com and www.
easyderm.net.
Statements included in this press release that are not historical in nature are "forward-looking statements"
within the meaning of the Private Securities Litigation Reform Act of 1995. The Company cautions readers that
forward-looking statements are subject to certain risks and uncertainties, which could cause actual results to
differ materially and which are identified from time to time in the Company’s reports filed with the U.S.
Securities and Exchange Commission. PluroGen Therapeutics, Inc. claims the protection of the Safe Harbor for
forward-looking statements contained in the Private Securities Litigation Reform Act of 1995.
Information included on PluroGen Therapeutics, Inc. and Welcare Industries, S.p.a. website is not incorporated herein
by reference or otherwise.
© PluroGen Therapeutics, Inc. 2009
President & CEO
11 May 2009 Board of Directors
443 994 0101
PLUROGEN THERAPEUTICS INC. & WELCARE INDUSTRIES, S.p.a.
SIGN LETTER OF INTENT TO
COMMERCIALIZE PLUROGEL™ - BASED PRODUCTS IN THE US
(Charlottesville, VA, May 12, 2009) – PluroGen Therapeutics, Inc. today announced a Letter of Intent with
Welcare Industries S.p.a. (Orvieto, Italy) to submit for US medical device approval and commence sales in
the US market of Welcare’s PluroGel™-based wound & skin cleansing product line.
Commenting on the Letter of Intent, Neal G. Koller, President & CEO of PluroGen, said, “We are pleased
Welcare has seen success in Europe with their PluroGel™-based skin & wound cleansing medical device
line and is now ready to bring these products to the US market. This is a terrific commercial opportunity
for PluroGen furthering our marketing strategy to offer multiple products with a variety of purposes based
on our core gel technology.”
Fulvia Lazzarotto, Managing Director for Welcare, commented that “We are looking forward to duplicating
the European success of our PluroGel™ based products in the US market. We are very happy PluroGen
will be working with us for this project, they are the ideal partner”.
About PluroGen Therapeutics, Inc.
PluroGen is a skin care and wound healing company commercializing our core patent-protected gel
technology platform that provides superior and differentiated physical, bio-impact and multi-function
benefits. Our multiple technology platforms are configurable to deliver drug and non-drug compounds as
protected and advanced therapeutic and topical products for simple and complex skin care, burn and
wound healing. PluroGen’s product pipeline targets improved, protected therapies for the 6 areas of
treatment in tissue management and healing (cleansing, infection, pain, inflammation, tissue salvage,
tissue regeneration).
PluroGen’s first gels, PluroGel™ and ActiviGel™, are being used initially in skin and wound cleansing
products, for personal skin care products and for two branded topical antimicrobial products, PluroGel™
Barrier Gels and PluroGel™ Barrier Dressings. PluroGel™ / ActiviGel™ technology is currently in routine use
at the University of Virginia Medical Center, having shown superior results on more than 2,000 patients in
two different patient populations, severe burns and chronic wounds. The PluroGen management and
operational teams, Boards and Principal Investigators are recognized global clinical and commercial
leaders in PluroGen’s target markets of burn and wound care and in the life sciences industry.
For more information about PluroGen Therapeutics, Inc., visit the Company’s web site at www.plurogen.com.
About the Welcare Industries, S.p.a.
Welcare Industries, S.p.a. is a privately held European medical device company with manufacturing,
distribution and headquarters in Orvieto, Italy. Welcare was founded in 1997 and focuses on wound and
total patient cleansing products, clinical and patient protection products and specialty procedure products.
Welcare is currently selling its products in major European countries.
For more information about Welcare Industries, S.p.a., visit the Company’s web site at www.welcaremedical.com and www.
easyderm.net.
Statements included in this press release that are not historical in nature are "forward-looking statements"
within the meaning of the Private Securities Litigation Reform Act of 1995. The Company cautions readers that
forward-looking statements are subject to certain risks and uncertainties, which could cause actual results to
differ materially and which are identified from time to time in the Company’s reports filed with the U.S.
Securities and Exchange Commission. PluroGen Therapeutics, Inc. claims the protection of the Safe Harbor for
forward-looking statements contained in the Private Securities Litigation Reform Act of 1995.
Information included on PluroGen Therapeutics, Inc. and Welcare Industries, S.p.a. website is not incorporated herein
by reference or otherwise.
© PluroGen Therapeutics, Inc. 2009